Drug Profile
Research programme: CCR10 antagonist - Spexis
Alternative Names: POL7085Latest Information Update: 16 Feb 2022
Price :
$50
*
At a glance
- Originator Polyphor
- Developer Spexis
- Class Cyclic peptides
- Mechanism of Action CCR10 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Asthma; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in Switzerland (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Switzerland (Parenteral)
- 23 Nov 2011 Preclinical trials in Inflammation in Switzerland (Parenteral)